Nuvelo CEO Ted Love: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
A day after Nuvelo releases disappointing Phase III results for Bayer-partnered alfimeprase, Love discusses Nuvelo’s next steps for the thrombolytic, and other options in the company’s pipeline.
You may also be interested in...
Nuvelo To Consider In-Licensing Deals In Wake Of Negative Alfimeprase Data
The firm halts enrollment of trials of the thrombolytic pending further review by outside experts and monitoring board.
Bay Area Biotech Roundtable: What Does It Take To Excel In The Global Marketplace? (Part 1 of 3)
Avigen, Genomic Health, Nuvelo, Poniard and Rigel execs sit down with “The Pink Sheet” DAILY to discuss pharma/biotech deal flow and secrets to the Bay Area’s biotech success.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.